NTX-801 / Nimbus Therap - LARVOL DELTA

Targeting CBL and CBLB ubiquitin ligases to exhaust cancer stem cells in metastatic breast cancer (AACR 2025) - "We generated a unique mouse model in which the C3(1)-TAg transgene drives mammary tumors known to resemble human triple-negative breast cancer (TNBC) and floxed-Cbl and Cblb genes can be inducibly deleted using tamoxifen (via CreERT2). Our results establish a tumor-intrinsic requirement of CBL/CBL-B to maintain breast cancer CSCs and add a critical second rationale for the use of chemical inhibitors of CBL/CBL-B as targeted therapeutics to counter BC recurrence and metastasis."

Cancer stem • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CBL • CBLB

Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting (Businesswire) - "Nimbus Therapeutics...is sharing preclinical data, released today, on its Casitas B-lineage lymphoma b (Cbl-b) inhibitor, NTX-801, at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, LA....The inhibitor NTX-801 demonstrated strong immune cell activation and robust and statistically significant tumor growth inhibition in a mouse syngeneic tumor model."

Preclinical • Oncology • Solid Tumor

Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting (Businesswire) - "Nimbus Therapeutics...announced that it will present preclinical data from its Casitas B-lineage lymphoma b (Cbl-b) program at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, LA."

Preclinical • Hematological Malignancies • Lymphoma • Oncology